1. Yeah, I agree with you, which is why I actively engage. 2....

1. Yeah, I agree with you, which is why I actively engage.

2. Show me where I have been wrong over there. I think you will find it much easier to source instances where IMU management have been very selective with information to suit their narrative, my man.

My agenda is purely disliking management misinforming investors that don't know any better, and then investors who think they have it mapped out misinforming those who rely on HC for perspective.

For example, IMU management were targeting HER-Vaxx for jurisdictions where Herceptin was not available/affordable, but had no problem publishing material suggesting the market size for HER-Vaxx was comparable to Herceptin. That's before we go into detail about study design, no head-to-head comparison in follow-up P2 trials, and the absolute joke about safety. The only safety concern for Herceptin was cardiotoxicity.

I was telling people the data was terrible despite the IDMC cutting the HERVaxx trial short, and I'm doing the same now because it is.